Klotho Conference Advances Research on Aging and Disease Prevention
TL;DR
The Klotho Conference showcased new therapeutic approaches like mRNA-LNP that could give companies a first-mover advantage in the emerging longevity market.
Researchers presented Klotho's molecular pathways, clinical translation progress, and diagnostic advances from 4,390 published papers to actionable healthspan extension strategies.
Klotho research advances could extend healthy aging, reduce age-related diseases, and improve quality of life for millions through regenerative therapies.
The Klotho gene discovered in 1997 now shows potential for reversing aging effects from brain health to organ regeneration.
Found this article helpful?
Share it with your network and spread the knowledge!
The inaugural Klotho Conference & Scientific Seminar united leading researchers, clinicians, and innovators to discuss recent advances in Klotho biology, representing a pivotal effort to translate foundational research into actionable strategies for healthspan extension. Research presented at the conference established clear connections between low Klotho levels and numerous age-related conditions, with evidence indicating that low circulating Klotho accelerates aging, increases cancer risk, and leads to earlier decline in cognition and memory with higher likelihood of brain disorders. Low Klotho also correlates with higher risk of heart failure, kidney failure, increased calcification and inflammation, muscle atrophy, and sarcopenia. Additional associations include impacts on mental health, sexual health, joint osteoarthritis, epileptic seizures in those under 65, hair loss, skin damage, vision deterioration, hearing loss, osteoporosis, oxidative stress, mitochondrial dysfunction, susceptibility to infections, slower wound healing, accelerated telomere shortening, and epigenetic age acceleration.
Therapeutic approaches discussed included Carmela Abraham's presentation on a Klotho-mRNA-LNP approach to increasing Klotho levels. Dr. Assumpció Bosch outlined preclinical progress in Klotho gene therapy for ALS, while Dr. Dena Dubal and Dr. Miguel Chillon examined Klotho's neuroprotective role and potential for gene therapy applications in brain health. Dr. Ido Wolf and Dr. Tamar Rubinek summarized research on Klotho's potential in malignant tumor suppression. Other sessions explored Klotho's role in inflammation, with Dr. Iliya Lefterov and Dr. Radosveta Koldamova discussing how Klotho signaling intersects with inflammatory pathways. A panel including Dr. Mona EzzatVilinov and fitness expert Ramona Braganza examined Klotho's role in muscle regeneration and functional mobility.
Dr. Gail Humble discussed Klotho's applications in medical aesthetics for skin, hair, and tissue regeneration, while Dr. Doris Taylor presented on Klotho's regenerative applications for organs and cardiovascular tissue. Dr. Ian White delivered a keynote outlining the translational path for Klotho therapies, including how naturally derived human Klotho sources can move into clinical trial phases. Dr. Joseph Cleaver synthesized scientific insight with practical applications in a luncheon keynote on lifestyle, aging, and Klotho. The conference catalyzed new partnerships among academic institutions, biotech companies, and longevity-focused investor networks, with several research groups indicating plans to accelerate clinical development of Klotho-based gene therapies.
With 4,390 papers published on Klotho since 1997, the conference reinforced the unified mission of raising Klotho biology into mainstream medical and therapeutic strategy to promote healthy aging. Future conferences will expand to include translational clinical trials, diagnostics development, and policy frameworks to bring Klotho therapies to patients responsibly and equitably. A short highlight reel of the event is available at https://youtu.be/ngH6qERXwRI, while a complete playlist of all presentations can be found at https://www.youtube.com/playlist?list=PLIzjBuzofFehaUfXU0GdvI2X8cr3gm6SY.
Curated from Newsworthy.ai
